+1 (888) 794-0077 Twitter LinkedIn

Overview

Title: Addressing Safety Testing of Drug Metabolites (MIST) in Drug Development

Summary

Our latest webinar discusses the importance of MIST, taking you through a case study and covering the following topics:
• Regulatory Guidance
• Why to Conduct MIST in Drug Development
• When to Conduct MIST in Drug Development
• When and How to Conduct Met ID to Address MIST

Speaker

Peter Wang
Dr. Peter Wang is the Senior Director of Drug Metabolism and Biotransformation at WuXi AppTec, Lab Testing Division. In his current role, he directs operations of the Drug Metabolism department, providing operational, client, and project management support. Dr. Wang has extensive experience in metabolite identification, having worked in in vitro and in vivo DMPK-related fields for more than 15 years. Prior to joining WuXi AppTec in 2008, Peter was a senior scientist at FMC Cooperation, where he served as Study Director for agrochemical metabolism studies in plants and animals.

 

Register Now

Experts at WuXi AppTec Laboratory Testing Division are happy to answer any questions you may have about moving your compound through the drug development process. Visit our blog and follow us on LinkedIn for more insights.